Biotechnology Companies By Net Asset

Net Asset
Net AssetEfficiencyMarket RiskExp Return
1ABBV AbbVie Inc
134.71 B
 0.38 
 0.89 
 0.34 
2AMGN Amgen Inc
97.15 B
 0.02 
 1.39 
 0.03 
3GILD Gilead Sciences
62.12 B
(0.06)
 1.83 
(0.11)
4NERV Minerva Neurosciences
56.9 B
(0.08)
 10.02 
(0.78)
5GMAB Genmab AS
35.29 B
(0.11)
 2.10 
(0.23)
6HLN Haleon Plc
34.81 B
 0.02 
 1.45 
 0.03 
7REGN Regeneron Pharmaceuticals
33.08 B
 0.25 
 1.11 
 0.27 
8BIIB Biogen Inc
26.84 B
(0.05)
 1.70 
(0.08)
9BNTX BioNTech SE
23.28 B
(0.08)
 2.18 
(0.17)
10VRTX Vertex Pharmaceuticals
22.73 B
 0.16 
 2.03 
 0.32 
11GRFS Grifols SA ADR
21.53 B
(0.07)
 5.42 
(0.41)
12MRNA Moderna
18.43 B
 0.08 
 3.94 
 0.31 
13UTHR United Therapeutics
7.17 B
(0.05)
 1.63 
(0.09)
14BMRN Biomarin Pharmaceutical
6.84 B
(0.08)
 1.53 
(0.12)
15INCY Incyte
6.78 B
 0.06 
 2.03 
 0.12 
16EXAS EXACT Sciences
6.47 B
(0.07)
 2.65 
(0.19)
17BGNE BeiGene
5.81 B
(0.03)
 3.30 
(0.10)
18GLPG Galapagos NV ADR
4.73 B
(0.08)
 1.72 
(0.13)
19IMAB I Mab
4.07 B
 0.07 
 6.27 
 0.44 
20ALNY Alnylam Pharmaceuticals
3.83 B
(0.05)
 2.61 
(0.14)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund. Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.